Suzuken : Reports Fiscal 2025 Full-Year Financial Results

May 14, 2026

Consolidated Financial Resultsfor the Fiscal Year Ended March 31, 2026 (Under Japanese GAAP)

Company name: SUZUKEN CO.,LTD.

Listing: Tokyo Stock Exchange, Nagoya Stock Exchange, Sapporo Securities Exchange Securities code: 9987

URL: https://www.suzuken.co.jp/en/

Representative: Shigeru Asano President and CEO

Inquiries: Satoshi Hashimoto Executive Officer and General Manager of Business Administration Department Telephone: +81-52-961-2331

Scheduled date of annual general meeting of shareholders: June 24, 2026 Scheduled date to commence dividend payments: June 3, 2026

Scheduled date to file annual securities report: June 22, 2026 Preparation of supplementary material on financial results: Yes

Holding of financial results briefing: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the fiscal year ended March 31, 2026 (from April 1, 2025 to March 31, 2026)

1. Consolidated operating results (Percentages indicate year-on-year changes.)

   	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent
   Fiscal year ended March 31, 2026 March 31, 2025	Millions of yen 2,486,647 2,399,952	% 3.6 0.6	Millions of yen 36,374 37,125	% (2.0) 6.4	Millions of yen 39,744 38,830	% 2.4 1.2	Millions of yen 38,136 34,496	% 10.6 18.9

   Note: Comprehensive income	For the fiscal year ended March 31, 2026:	¥	41,371 million	[	58.5%]
   	For the fiscal year ended March 31, 2025:	¥	26,108 million	[	(27.9) %]

   	Basic earnings per share	Diluted earnings per share	Rate of return on equity	Ordinary profit to total assets ratio	Operating profit to net sales ratio
   Fiscal year ended	Yen	Yen	%	%	%
   March 31, 2026	545.54	-	9.3	3.5	1.5
   March 31, 2025	454.58	-	8.4	3.3	1.5

   Reference: Share of profit (loss) of entities accounted for using equity method

   For the fiscal year ended March 31, 2026:	¥	1,030 million
   For the fiscal year ended March 31, 2025:	¥	(636) million

2. Consolidated financial position

   	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
   As of March 31, 2026 March 31, 2025	Millions of yen 1,155,766 1,113,831	Millions of yen 416,012 407,420	% 36.0 36.6	Yen 6,148.58 5,651.56

   Reference: Equity

   As of March 31, 2026:	¥	415,876 million
   As of March 31, 2025:	¥	407,291 million

3. Consolidated cash flows

Note: The Company plans to conduct a 2-for-1 stock split of common stock effective October 1, 2026. The forecast year-end dividend per share for the fiscal year ending March 31, 2027 reflects the impact of this stock split, and therefore the total annual dividend per share is listed as “-.” If the stock split is not taken into account, the forecast year-end dividend per share for the fiscal year ending March 31, 2027 would be ¥60, and the total annual dividend would be ¥120.

3. Consolidated financial result forecasts for the fiscal year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentages indicate year-on-year changes.)

Note: The Company plans to conduct a 2-for-1 stock split of common stock effective October 1, 2026. Basic earnings per share for the full year in the financial result forecasts for the fiscal year ending March 31, 2027 reflects the impact of this stock split. If the stock split is not taken into account, basic earnings per share would be ¥369.62.

1. Changes in accounting policies, changes in accounting estimates, and restatement

   1. Changes in accounting policies due to revisions to accounting standards and other regulations: None

   2. Changes in accounting policies due to other reasons: None

   3. Changes in accounting estimates: None

   4. Restatement: None

2. Number of issued shares (common shares)

   1. Total number of issued shares at the end of the period (including treasury shares)

      As of March 31, 2026	72,167,204 shares
      As of March 31, 2025	72,167,204 shares

   2. Number of treasury shares at the end of the period

      As of March 31, 2026	4,529,359 shares
      As of March 31, 2025	100,049 shares

   3. Average number of shares outstanding during the period

1. Non-consolidated financial results for the fiscal year ended March 31, 2026 (from April 1, 2025 to March 31, 2026)

1. Non-consolidated operating results (Percentages indicate year-on-year changes.)

   	Net sales		Operating profit		Ordinary profit		Profit
   Fiscal year ended March 31, 2026 March 31, 2025	Millions of yen 2,299,677 2,210,854	% 4.0 1.0	Millions of yen 22,713 23,934	% (5.1) 1.3	Millions of yen 28,181 28,763	% (2.0) 0.8	Millions of yen 29,239 25,732	% 13.6 22.2

   	Basic earnings per share	Diluted earnings per share
   Fiscal year ended	Yen	Yen
   March 31, 2026	418.27	-
   March 31, 2025	339.09	-

2. Non-consolidated financial position

Reference: Equity

• Financial results reports are exempt from audit conducted by certified public accountants or an audit firm.

• Proper use of earnings forecasts, and other special matters

  Earnings forecasts and other statements about the future that are included in this material are based on information currently in the possession of the Company, and certain conditions judged reasonable by the Company. These statements do not guarantee that the Company will achieve its earnings forecasts. In addition, actual results, etc., may differ significantly due to various factors. For notes, etc., on the conditions for earnings forecasts and the use of earnings forecasts, please refer to “1. Overview of Operating Results (4) Future Prospects” on page 7 of the attached documentation.

  Contents of Attached Documentation

  1. Overview of Operating Results 2

     1. Overview of Operating Results for the Fiscal Year 2

     2. Overview of Financial Condition for the Fiscal Year 6

     3. Overview of Cash Flow for the Fiscal Year 6

     4. Future Prospects 7

     5. Basic Policy on Profit Distribution and Dividends for the Current and Next Fiscal Years 8

  2. Status of the Group 9

  3. Management Policy 12

     1. Company’s Basic Management Policy 12

     2. Targeted Management Indicators 12

     3. Company’s Medium- to Long-term Management Strategy 13

  4. Basic Policy on Selection of Accounting Standards 14

  5. Consolidated Financial Statements and Key Notes 15

     1. Consolidated Balance Sheets 15

     2. Consolidated Statements of Income and Comprehensive Income 17

        Consolidated Statements of Income 17

        Consolidated Statements of Comprehensive Income 18

     3. Consolidated Statements of Changes in Shareholders’ Equity 19

     4. Consolidated Statements of Cash Flows 23

     5. Notes on Consolidated Financial Statements 25

25 25 25 30 30

―1—

1. Overview of Operating Results(1) Overview of Operating Results for the Fiscal Year

(Millions of yen)

During the fiscal year ended March 31, 2026, we saw continued currency market fluctuations and inflation reflecting rising

prices of electrical power, energy, and raw materials for multiple reasons, including uncertainties about the policy trends of the US administration. Furthermore, alongside the policy-driven wage hikes, the increasing labor shortages, symbolized by the so-called “2024 Problem,” have led to rising costs across various areas. Meanwhile, with uncertainty surrounding the ability to pass on

these costs through price increases, as well as the uncertainty regarding the impact on crude oil prices and product procurement stemming from heightened tensions in the Middle East that surfaced toward the end of the fiscal year, among other factors, the outlook for the domestic economy and corporate earnings has continued to remain unclear.

Under these circumstances, the Suzuken Group formulated a Medium-Term Management Plan covering the period through the fiscal year ended March 31, 2026 . Through the implementation of this plan, the Group advanced its transformation into a health creation enterprise working as “One Team,” aiming to create new value as an entity that continues to provide new solutions and hope for the changing healthcare ecosystem, thereby further enhancing corporate value and contributing to solving social issues. Leading up to the 100th anniversary of our founding in 2032, we positioned “Reform of existing businesses” and “Preparation for new growth businesses” as our main focuses and took steps to advance these initiatives.

During the fiscal year ended March 31, 2026, we worked on several measures as part of the “Reform of existing businesses,” including reinforcing the distribution model for specialty drugs, such as orphan drugs and regenerative medicine products, through collaboration with various companies, as well as creating a new profit model through MS*1 activities.

Specifically, in order to build a healthcare distribution platform, we worked on enhancing the quality of our pharmaceutical distribution by implementing Cubixx, a specialty drug traceability solution, at regional core hospitals and other medical

institutions nationwide. In the distribution of specialty drugs, we addressed the requirements of pharmaceutical companies

seeking market entry and new product launches in Japan, while strengthening our distribution base to ensure the reliable delivery of new drugs to patients awaiting treatment. As a result, as of the end of the fiscal year, a total of 710 units were in operation across 597 customers nationwide, with adoption exceeding half of designated cancer care hospitals and reaching approximately 80% of national university hospitals. Looking ahead, in addition to further promoting the adoption of Cubixx, we will enhance its functionality through integration with peripheral services, enabling more accurate data acquisition, improved visibility of

distribution inventory, and demand forecasting using inventory and consumption data.

As an initiative aimed at strengthening the distribution infrastructure, we established the Greater Tokyo Distribution Center in Soka City, Saitama Prefecture, and commenced full operations in April 2024. It is the industry’s first complex distribution center that incorporates a contract manufacturing and manufacturer distribution area within a wholesale distribution base, employing cutting-edge robotic technology for enhanced automation and labor efficiency. Additionally, in May 2025, we entered into a land sale agreement with Kasugai City in Aichi Prefecture and acquired land for the development of a new logistics hub, tentatively named the Chubu Distribution Center, to serve the Chubu region (central Japan) (with construction scheduled to start in October 2027). In the future, we aim to achieve a variety of benefits, including improved efficiency through automation, reduced transportation and delivery costs, quality assurance that complies with GDP*2 standards, environmental benefits such as reduced CO2 emissions, and further strengthening our BCP response in the event of a disaster by maximizing the use of the Group’s

distribution network, starting with both the Greater Tokyo Distribution Center and Chubu Distribution Center.

Moving forward, the Suzuken Group will continue to sequentially introduce and implement new initiatives to realize the “Reform of existing businesses.”

For “Preparation for new growth businesses,” the Suzuken Group has been working with its partner companies to establish new distribution channels, accelerate the development of digital health businesses through collaborations, and advance innovative

services and information businesses, in order to provide new value to pharmaceutical companies, medical institutions, pharmacies, and patients.

Specifically, we have launched services through the COLLABO Portal*3, a portal site for medical and nursing care

professionals. In addition to delivering various services and information offered by the Suzuken Group, the COLLABO Portal is equipped with functions that connect customers with the Suzuken Group, pharmaceutical companies, and multidisciplinary

healthcare professionals and specialist staff. It also enables the integrated delivery of digital health services from partner companies. Through these initiatives, we have worked to create a safe and secure environment in which digital health services can be utilized in medical and nursing care settings.

In addition, we approved and completed (effective April 1, 2026) the merger and integration of Collabo Square Co., Ltd., which operates the COLLABO Portal, and Embrace Co., Ltd., which operates Medical Care Station (MCS)*4 , a medical and nursing care collaboration platform. Through our initiatives during the period of this Medium-Term Management Plan, new connections have been established between the Company and over 440,000 (user IDs) medical and nursing care professionals.

―2—